Life Sciences R&D & Medical

ZS recognized for life sciences R&D RWE and RWD in new IDC report

Oct. 8, 2023 | Analyst Report | 2-minute read

ZS recognized for life sciences R&D, RWE and RWD in new IDC report




IDC MarketScape recently named ZS a Leader in strategic life sciences R&D RWE and RWD.

 

According to the “IDC MarketScape: Worldwide Life Science R&D RWE, RWD, Platforms, Technologies, and Consulting Services 2023 Vendor Assessment” (doc #US51186723, September 2023): “ZS offers comprehensive advisory and transformation services, including identifying unmet medical needs, improving clinical development plans and generating evidence on real-world outcomes for patients, providers and payers. Its top use cases include data excellence, RWD analytics (disease understanding, patient journey, computational phenotyping, evidence generation and clinical trial optimization) and regulatory RWE.”

“As R&D organizations seek to mitigate risk, reduce costs and accelerate timelines, real-world data and real-world evidence are playing a critical role.”

Pratap Khedkar, CEO, ZS


IDC, a global provider of market intelligence, advisory services and events, designed this vendor assessment to evaluate vendors based on capabilities and strategies in this market. This year marks the first time IDC performed this assessment in this market.

 

“Insights generated from real-world data constitute the elixir that is fueling innovation, accelerating recruitment, and providing the much-needed patient 360 view to improve patient outcomes. The ability to leverage technology and deep expertise for developing an integrated evidence generation strategy to power regulatory approvals, accelerate market launch, and increase patient access is the need of the hour,” said Dr. Nimita Limaye, research VP, life sciences R&D strategy and technology, IDC.

 

ZS CEO Pratap Khedkar said the report highlights ZS’s deep domain expertise in analytics, operations support, strategy and technology across the pharma product life cycle. It also anticipates the company’s ongoing investment in research and development.

 

“As R&D organizations seek to mitigate risk, reduce costs and accelerate timelines, real-world data and real-world evidence are playing a critical role,” Khedkar said. “Our people are passionate about continuing to use data and analytics to help bring more therapies to market and improve patient outcomes.”

Source: “IDC MarketScape: Worldwide Life Science R&D RWE, RWD, Platforms, Technologies, and Consulting Services 2023 Vendor Assessment,” by Nimita Limaye (doc #US51186723, September 2023). Copyright IDC.

IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of ICT (information and communications technology) suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.

Add insights to your inbox

We’ll send you content you’ll want to read – and put to use.